Treatment patterns, health care resource use and outcomes in metastatic triple-negative breast cancer in Germany: retrospective chart review study (OBTAIN)

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer

“…In our TNBC population, mean age of the overall cohort was comparable to reports from other population‐based studies 5,11,14‐16,30,31 . Most BCs are diagnosed at an early stage; in Canada, <5% are diagnosed at stage IV 32 .…”

“…In our TNBC population, mean age of the overall cohort was comparable to reports from other population-based studies. 5,11,[14][15][16]30,31 Most BCs are diagnosed at an early stage; in Canada, <5% are diagnosed at stage IV. 32 In our study, 5.8% of TNBCs were metastatic at diagnosis, which is in line with other reports.…”

“…[3][4][5] Population-based studies focused on TNBC are sparse and the majority address only clinical characteristics and outcomes. 3,[5][6][7][8][9][10][11][12][13][14][15][16] While older data report direct health-care costs for Ontario BC patients by cancer stage, 17 there are no published reports on resource utilization in an Ontario TNBC cohort by cancer stage. We sought to assess the occurrence, management, and resource utilization according to early versus de novo metastatic disease in Ontario women diagnosed with TNBC.…”

“…Population‐based studies focused on TNBC are sparse and the majority address only clinical characteristics and outcomes 3,5‐16 . While older data report direct health‐care costs for Ontario BC patients by cancer stage, 17 there are no published reports on resource utilization in an Ontario TNBC cohort by cancer stage.…”

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study

“…In the E2100, AVADO, RIBBON-1, and MERiDiAN randomized phase III trials, combining bevacizumab with first-line chemotherapy for HER2-negative MBC significantly improved progression-free survival (PFS) versus chemotherapy alone [1][2][3][4] but overall survival was not improved. Bevacizumab is approved in Europe as first-line therapy for HER2-negative MBC in combination with either paclitaxel or capecitabine, and is considered a standard of care option in some countries, particularly in patients with triple-negative MBC [5]. Although taxane-based regimens are among the most active in MBC, chemotherapy-induced peripheral neuropathy with microtubule inhibitors can be disabling [6].…”